Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding Study - Optimi Health Corporation (ClinicalTrials.gov, 2023)

Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. - Sloshower J; Skosnik PD; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC. (2023)

Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review. - Sharma R; Batchelor R; Sin J. (2023)

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD - Ching THW; Grazioplene R; Pittenger C; Kelmendi B. (PsyArXiv, 2023)

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD (PsyArXiv, 2023)

Trends in drug use among nightclub and festival attendees in New York City, 2017-2022. - Palamar JJ; Le A; Cleland CM; Keyes KM. (2023)

Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health. - Ryan RS; Copello A; Fox AP (BMC psychiatry, 2023)

The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice. - Zanikov T; Gerasymchuk M; Ghasemi Gojani E; Robinson GI; Asghari S; Groves A; Haselhorst L; Nandakumar S; Stahl C; Cameron M; Li D; Rodriguez-Juarez R; et al. (2023)

Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. - Brett J; Knock E; Korthuis PT; Liknaitzky P; Murnane KS; Nicholas CR; Patterson JC; Stauffer CS. (2023)

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder - New York State Psychiatric Institute (ClinicalTrials.gov, 2023)

A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to Depression. - Hibicke M; Kramer HM; Nichols CD. (2023)

Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice. - Aday JS; Skiles Z; Eaton N; Fredenburg L; Pleet M; Mantia J; Bradley ER; Fernandes-Osterhold G; Woolley JD. (2023)

Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders. - Wulff AB; Nichols CD; Thompson SM. (2023)

Understanding psychedelic 'mystical experience'-A case example - Turkia M. (PsyArXiv, 2023)

Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD-A retrospective case study - Turkia M. (PsyArXiv, 2023)

Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin-A retrospective case study - Turkia M. (PsyArXiv, 2023)

Understanding psychedelic 'mystical experience'-A case example (PsyArXiv, 2023)

Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD-A retrospective case study (PsyArXiv, 2023)

Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin-A retrospective case study (PsyArXiv, 2023)

Next generation antidepressants with novel mechanisms for treatment resistant depression. - Chen MH; Tu PC; Su TP. (2023)

Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice. - Glatfelter GC; Naeem M; Pham DNK; Golen JA; Chadeayne AR; Manke DR; Baumann MH. (2023)

Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020. - Kopra EI; Ferris JA; Winstock AR; Kuypers KP; Young AH; Rucker JJ. (2023)

The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study. - Kinderlehrer DA. (2023)

Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist's Training? - Emmerich N; Humphries B. (2023)

Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review. - Lazur J; Hnatyk K; Kała K; Sułkowska-Ziaja K; Muszyńska B. (2023)

Research into Psychedelic-Assisted Psychotherapy for Anorexia Nervosa Should be Funded. - Otterman LS (Journal of bioethical inquiry, 2023)

Interaction of psychedelic tryptamine derivatives with a lipid bilayer. - Zohairi F; Khandelia H; Hakami Zanjani AA (Chemistry and physics of lipids, 2023)

Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. - Jha MK; Mathew SJ. (2023)

Default Mode Network Modulation by Psychedelics: A Systematic Review. - Gattuso JJ; Perkins D; Ruffell S; Lawrence AJ; Hoyer D; Jacobson LH; Timmermann C; Castle D; Rossell SL; Downey LA; Pagni BA; Galvão-Coelho NL; et al. (2023)

National Institutes of Health psilocybin research speaker series: State of the science, regulatory and policy landscape, research gaps, and opportunities. - Xi D; Berger A; Shurtleff D; Zia FZ; Belouin S. (2023)

Synapses, predictions, and prediction errors: A neocortical computational study of MDD using the temporal memory algorithm of HTM. - Sherif MA; Khalil MZ; Shukla R; Brown JC; Carpenter LL. (2023)

UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice - Rijsketic DR; Casey AB; Barbosa DA; Zhang X; Hietamies TM; Ramirez-Ovalle G; Pomrenze M; Halpern CH; Williams LM; Malenka RC; Heifets BD. (bioRxiv, 2023)

Acute psilocybin enhances cognitive flexibility in rats. - Torrado Pacheco A; Olson RJ; Garza G; Moghaddam B. (2023)

Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition - Mallaroni P; Mason NL; Reckweg JT; Paci R; Ritscher S; Toennes SW; Theunissen EL; Kuypers KP; Ramaekers JG. (bioRxiv, 2023)

Rearing behaviour in the mouse behavioural pattern monitor distinguishes the effects of psychedelics from those of lisuride and TBG. - Chen Y; Liu J; Yao Y; Yan H; Su R. (2023)

Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis. - Crowe M; Manuel J; Carlyle D; Lacey C. (2023)

Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample. - Jones G; Lipson J; Wang E. (2023)

Therapeutic effect of psilocybin in addiction: A systematic review. - van der Meer PB; Fuentes JJ; Kaptein AA; Schoones JW; de Waal MM; Goudriaan AE; Kramers K; Schellekens A; Somers M; Bossong MG; Batalla A. (2023)

Cannabis-assisted psychotherapy for complex dissociative posttraumatic stress disorder: A case report. - Ragnhildstveit A; Kaiyo M; Snyder MB; Jackson LK; Lopez A; Mayo C; Miranda AC; August RJ; Seli P; Robison R; Averill LA. (2023)

Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. - Goodwin GM; Aaronson ST; Alvarez O; Atli M; Bennett JC; Croal M; DeBattista C; Dunlop BW; Feifel D; Hellerstein DJ; Husain MI; Kelly JR; et al. (2023)

Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?-A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines. - Henríquez-Hernández LA; Rojas-Hernández J; Quintana-Hernández DJ; Borkel LF. (2023)

5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines. - Cameron LP; Patel SD; Vargas MV; Barragan EV; Saeger HN; Warren HT; Chow WL; Gray JA; Olson DE (ACS chemical neuroscience, 2023)

Psilocybin therapy for depression. A good trip? - Rucker JJ. (2023)

Psilocybin for Treatment-Resistant Depression. - Østergaard SD; Hieronymus F. (2023)

Intoxication of dogs and cats with common stimulating, hallucinogenic and dissociative recreational drugs. - Oster E; Čudina N; Pavasović H; Prevendar Crnić A; Božić F; Fadel C; Giorgi M. (2023)

SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression - Washington University School of Medicine (ClinicalTrials.gov, 2023)

Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'. - von Rotz R; Schindowski EM; Jungwirth J; Schuldt A; Rieser NM; Zahoranszky K; Seifritz E; Nowak A; Nowak P; Jäncke L; Preller KH; Vollenweider FX. (2023)

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation. - Modlin NL; Miller TM; Rucker JJ; Kirlic N; Lennard-Jones M; Schlosser D; Aaronson ST. (2023)

Educational Materials and Image Induction Increase Treatment Credibility. - Low F; Earleywine M. (2023)

Psychedelics: Science sabotaged by Social Media. - Sellers EM; Romach MK. (2023)

Classic psychedelics do not affect T cell and monocyte immune responses. - Rudin D; Areesanan A; Liechti ME; Gründemann C. (2023)

Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective. - Stokłosa I; Więckiewicz G; Stokłosa M; Piegza M; Pudlo R; Gorczyca P. (2023)

Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder - Keith Heinzerling (ClinicalTrials.gov, 2023)

Utility of preclinical models in the study of psilocybin - A comprehensive review. - Pedicini M; Cordner ZA. (2023)

Psychedelics for Patients With Cancer: A Comprehensive Literature Review. - White CM; Weisman N; Dalo J. (2023)

Post-traumatic stress symptoms, post-traumatic stress disorder, and post-traumatic growth among cancer survivors: a systematic scoping review of interventions. - Capaldi JM; Shabanian J; Finster LB; Asher A; Wertheimer JC; Zebrack BJ; Shirazipour CH. (2023)

Indigenous-Amazonian Traditional Medicine's Usage of the Tobacco Plant: A Transdisciplinary Ethnopsychological Mixed-Methods Case Study. - Berlowitz I; García Torres E; Maake C; Wolf U; Martin-Soelch C. (2023)

Shared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin. - Davoudian PA; Shao LX; Kwan AC. (2023)

Are psychedelics the answer to chronic pain: A review of current literature. - Kooijman NI; Willegers T; Reuser A; Mulleners WM; Kramers C; Vissers KCP; van der Wal SEI. (2023)

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. - Mastinu A; Anyanwu M; Carone M; Abate G; Bonini SA; Peron G; Tirelli E; Pucci M; Ribaudo G; Oselladore E; Premoli M; Gianoncelli A; et al. (2023)

The association between naturalistic use of psychedelics and co-occurring substance use disorders. - Rabinowitz J; Lev-Ran S; Gross R. (2023)

Psilocin suppresses methamphetamine-induced hyperlocomotion and acquisition of conditioned place preference via D2R-mediated ERK signaling. - Wang J; Liang M; Shang Q; Qian H; An R; Liu H; Shao G; Li T; Liu X. (2023)

Conformational Landscape and Hydrogen Bonding Pattern of Psilocin: Computational Insights - Bhadoria Poonam; Ramanathan Venkatnarayan (ChemistrySelect, 2023)

Acute psilocybin enhances cognitive flexibility in rats - Pacheco AT; Olson RJ; Garza G; Moghaddam B. (bioRxiv, 2023)

When art therapy went chemical: Alfred Bader, pharmacology, and art brut, c.1950-1970s. - Martinovic J. (2023)

Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness. - Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D. (2023)

An Integrative Review of Measures of Spirituality in Experimental Studies of Psilocybin in Serious Illness Populations. - Baker KM; Ulrich CM; Meghani SH. (2023)

Et psykoanalytisk og et postmoderne perspektiv på selv/egoopløsning i en psykedelisk kontekst - Andersen S. (PsyArXiv, 2023)

Et psykoanalytisk og et postmoderne perspektiv på selv/egoopløsning i en psykedelisk kontekst (PsyArXiv, 2023)

Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice. - Alper K; Cange J; Sah R; Schreiber-Gregory D; Sershen H; Vinod KY. (2023)

Electrophysiological study of visual and auditory processing in psilocin-induced hallucinations: exploring evoked potentials and 5-HT2A receptor involvement - Vejmola Č.; Hubený J.; Koudelka V.; Griškova-Bulanova I.; Páleníček T. (Neuroscience Applied, 2022)

Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States. - Simonsson O; Goldberg SB (Journal of psychoactive drugs, 2022)

The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics. - Hadar A; David J; Shalit N; Roseman L; Gross R; Sessa B; Lev-Ran S (Journal of psychoactive drugs, 2022)

Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers. - Kious B; Schwartz Z; Lewis B (Journal of psychopharmacology (Oxford, England), 2022)

Psychedelic Drug Legislative Reform and Legalization in the US. - Siegel JS; Daily JE; Perry DA; Nicol GE. (2022)

Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective. - Henningfield JE; Ashworth J; Heal DJ; Smith SL. (2022)

Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models. - Ezeaka UC; Kim HJJ; Laprairie RB. (2022)

Functional MRI markers for treatment-resistant depression: Insights and challenges. - Kotoula V; Evans JW; Punturieri C; Johnson SC; Zarate CA (Progress in brain research, 2022)

The Resurgence of Hallucinogen Drugs in Clinical Research. - Rivera-García MT; Cruz SL. (2022)

Evaluation of Sensorimotor Gating Deficits in Mice Through Prepulse Inhibition (PPI) of the Startle Response. - Unzueta-Larrinaga P; Urigüen L. (2022)

Biological embedding of early trauma: the role of higher prefrontal synaptic strength. - Tamman AJF; Jiang L; Averill CL; Mason GF; Averill LA; Abdallah CG. (2022)

UNCOVERING THE UNTAPPED POTENTIAL OF PSILOCYBIN THERAPY IN ALLEVIATING CANCER-RELATED DEPRESSION: AN URGENT CALL TO RE-EVALUATE TREATMENT STRATEGIES. - Ahmed H; Mushahid H; Arshad T. (2022)

Efficacy and Safety of Psychedelics in Treating Anxiety Disorders. - Feulner L; Sermchaiwong T; Rodland N; Galarneau D. (2022)

Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment. - Edelsohn GA; Sisti D. (2022)

On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression. - Gukasyan N. (2022)

Is psilocybin an effective antidepressant and what is its Mechanism of action? - Mann JJ. (2022)

Editorial: What is up with psychedelics anyway? - Lewis CR; McMurray M; Mennenga SE; Helms Tillery S (Frontiers in neuroscience, 2022)

Corrigendum: Three naturally-occurring psychedelics and their significance in the treatment of mental health disorders. - Vorobyeva N; Kozlova AA (Frontiers in pharmacology, 2022)

Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and Strategies for Optimizing Experiences. - Shaw L; Rea K; Lachowsky NJ; Roth EA (Journal of psychoactive drugs, 2022)

Validation of a French Version of the Mystical Experience Questionnaire with Retrospective Reports of the Most Significant Psychedelic Experience among French Users. - Fauvel B; Kangaslampi S; Strika-Bruneau L; Roméo B; Piolino P (Journal of psychoactive drugs, 2022)

Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis. - Kelly JR; Clarke G; Harkin A; Corr SC; Galvin S; Pradeep V; Cryan JF; O'Keane V; Dinan TG (International journal of clinical and health psychology: IJCHP, 2022)

The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials. - IsHak WW; Garcia P; Pearl R; Dang J; William C; Totlani J; Danovitch I. (2022)

Psychedelics, entropic brain theory, and the taxonomy of conscious states: a summary of debates and perspectives. - Rankaduwa S; Owen AM (Neuroscience of consciousness, 2022)

Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique. - Mosurinjohn S; Roseman L; Girn M (Frontiers in psychiatry, 2022)

Mini-review: The neurobiology of treating substance use disorders with classical psychedelics. - Urban MM; Stingl MR; Meinhardt MW (Frontiers in neuroscience, 2022)

Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders. - Blest-Hopley G; Amit BH; O'Neill A; Ruffell SGD (Frontiers in psychiatry, 2022)

Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder. - Phan AN; Terry GE (Frontiers in psychiatry, 2022)

Medical student attitudes and perceptions of psychedelic-assisted therapies. - Li I; Fong R; Hagen M; Tabaac B (Frontiers in psychiatry, 2022)

Case report: Psychedelic-induced seizures captured by intracranial electrocorticography. - Blond BN; Schindler EAD (Frontiers in neurology, 2022)

Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study. - Hartong V; van Emmerik A (Journal of psychoactive drugs, 2022)

Altered states of leadership: mindfulness meditation, psychedelic use, and leadership development. - Simonsson O; Stenfors CUD; Goldberg SB; Hendricks PS; Osika W (Frontiers in psychology, 2022)

Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers. - Boehnke KF; Cox K; Weston C; Herberholz M; Glynos N; Kolbman N; Fields CW; Barron J; Kruger DJ (Frontiers in psychiatry, 2022)

The Association of Classic Serotonergic Psychedelic Use and Intention of Future Use with Nature Relatedness. - Longo MSC; Bienemann B; Multedo M; Negreiros MA; Schenberg E; Mograbi DC (Journal of psychoactive drugs, 2022)

Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials. - Herrmann Z; Earleywine M; De Leo J; Slabaugh S; Kenny T; Rush AJ (Journal of psychoactive drugs, 2022)

An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically. - Kruger DJ; Glynos NG; Fields CW; Herberholz M; Boehnke KF (Journal of psychoactive drugs, 2022)

Bedside to bench: the outlook for psychedelic research. - Acero VP; Cribas ES; Browne KD; Rivellini O; Burrell JC; O'Donnell JC; Das S; Cullen DK (Frontiers in pharmacology, 2022)

Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges. - Barnett BS; Bassir Nia A; Sackett NB; Weleff J (Frontiers in psychiatry, 2022)

"How Do I Learn More About this?": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics. - Kruger DJ; Enghoff O; Herberholz M; Barron J; Boehnke KF (Journal of psychoactive drugs, 2022)

Psychedelics, epilepsy, and seizures: a review. - Freidel N; Kreuder L; Rabinovitch BS; Chen FY; Huang RST; Lewis EC (Frontiers in pharmacology, 2022)

Psilocybin for Depression: From Credibility to Feasibility, What's Missing? - Munafò A; Arillotta D; Mannaioni G; Schifano F; Bernardini R; Cantarella G. (2022)

Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants. - Holze F; Becker AM; Kolaczynska KE; Duthaler U; Liechti ME. (2022)

Genome sequencing progenies of magic mushrooms (Psilocybe subaeruginosa) identifies tetrapolar mating and gene duplications in the psilocybin pathway. - McTaggart AR; James TY; Slot JC; Barlow C; Fechner N; Shuey LS; Drenth A. (2022)

A Review of Synthetic Access to Therapeutic Compounds Extracted from. - Serreau R; Amirouche A; Benyamina A; Berteina-Raboin S (Pharmaceuticals (Basel, Switzerland), 2022)

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. - von Rotz R; Schindowski EM; Jungwirth J; Schuldt A; Rieser NM; Zahoranszky K; Seifritz E; Nowak A; Nowak P; Jäncke L; Preller KH; Vollenweider FX. (2022)

Canalization and plasticity in psychopathology. - Carhart-Harris RL; Chandaria S; Erritzoe DE; Gazzaley A; Girn M; Kettner H; Mediano PAM; Nutt DJ; Rosas FE; Roseman L; Timmermann C; Weiss B; et al. (2022)

Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms. - Meccia J; Lopez J; Bagot RC. (2022)

The varieties of psychedelic law. - Marks M. (2022)

Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents. - Jones G; Arias D; Nock M. (2022)

Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment. - Meir P; Taylor L; Soares JC; Meyer TD. (2022)

Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines. - Heal DJ; Gosden J; Smith SL; Atterwill CK. (2022)

Phylogenomics of the psychoactive mushroom genus Psilocybe and evolution of the psilocybin biosynthetic gene cluster - Bradshaw AJ; Ramírez-Cruz V; Awan AR; Furci G; Guzmán-Dávalos L; Stamets P; Dentinger BT. (bioRxiv, 2022)

Effect of psilocybin on decision-making and motivation in the healthy rat. - Roberts BF; Zylko AL; Waters CE; Crowder JD; Gibbons WJ; Sen AK; Jones JA; McMurray MS. (2022)

"A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use. - DellaCrosse M; Pleet M; Morton E; Ashtari A; Sakai K; Woolley J; Michalak E. (2022)

Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption. - Morton E; Sakai K; Ashtari A; Pleet M; Michalak EE; Woolley J. (2022)

Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients. - Shnayder S; Ameli R; Sinaii N; Berger A; Agrawal M. (2022)

Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology. - Kelly DF; Kelly DF; Heinzerling K; Sharma A; Gowrinathan S; Sergi K; Mallari RJ. (2022)

Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. - Kelmendi B; Kichuk SA; DePalmer G; Maloney G; Ching THW; Belser A; Pittenger C. (2022)

Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation. - Burmester DR; Madsen MK; Szabo A; Aripaka SS; Stenbæk DS; Frokjaer VG; Elfving B; Mikkelsen JD; Knudsen GM; Fisher PM. (2022)

Update on treatments for anxiety-related disorders. - Lee HJ; Stein MB. (2022)

Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome. - Buzzelli V; Carbone E; Manduca A; Schiavi S; Feo A; Perederiy JV; Ambert KH; Hausman M; Trezza V. (2022)

Psychedelic-Induced Serotonin 2A Receptor Downregulation Does Not Predict Swim Stress Coping in Mice. - Pędzich BD; Medrano M; Buckinx A; Smolders I; De Bundel D. (2022)

Lower-dose psycholytic therapy - A neglected approach. - Passie T; Guss J; Krähenmann R. (2022)

Matrix-assisted laser-desorption/ionization-mass spectrometric imaging of psilocybin and its analogues in psychedelic mushrooms using a cesium chloride-coated target plate. - Wang H; Wang Y. (2022)

Direct Quantitation of Psilocybin and Psilocin by One-Dimensional 1H and 31P qNMR in a revived Greek specimen of Psilocybe cyanescens - Magiatis P; Dadiotis E; Antonopoulos R K; Ioannidis K; Mitsis V; Melliou E; Gonou-Zagou Z (Planta Medica, 2022)

Set and setting in microdosing: an oft-overlooked principle. - Hartogsohn I; Petranker R (Psychopharmacology, 2022)

Psychedelic-Assisted Therapy for People with Eating Disorders. - Gukasyan N; Schreyer CC; Griffiths RR; Guarda AS (Current psychiatry reports, 2022)

A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability. - Barber G; Nemeroff CB; Siegel S. (2022)

Therapeutic use of psilocybin: Practical considerations for dosing and administration. - MacCallum CA; Lo LA; Pistawka CA; Deol JK. (2022)

DNA Authentication and Chemical Analysis of Psilocybe Mushrooms Reveal Widespread Misdeterminations in Fungaria and Inconsistencies in Metabolites. - Bradshaw AJ; Backman TA; Ramírez-Cruz V; Forrister DL; Winter JM; Guzmán-Dávalos L; Furci G; Stamets P; Dentinger BTM. (2022)

Considerations in assessing the abuse potential of psychedelics during drug development. - Calderon SN; Bonson KR; Reissig CJ; Lloyd JM; Galati S; Chiapperino D. (2022)

Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression. - Shukuroglou M; Roseman L; Wall M; Nutt D; Kaelen M; Carhart-Harris R. (2022)

Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. - Schindler EAD; Sewell RA; Gottschalk CH; Luddy C; Flynn LT; Zhu Y; Lindsey H; Pittman BP; Cozzi NV; D'Souza DC. (2022)

Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis. - Irizarry R; Winczura A; Dimassi O; Dhillon N; Minhas A; Larice J. (2022)

Characterization of the Gateway Decarboxylase for Psilocybin Biosynthesis. - Schäfer T; Kramer K; Werten S; Rupp B; Hoffmeister D. (2022)

Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives. - Messell C; Summer L; Bonde LO; Beck BD; Stenbæk DS. (2022)

NW Trauma Therapies, Chronic Illness of Chronic Depression, PTSD, MS, HIV, and SARS-CoV-2, Long Haulers Syndrome. Treatment of Unregulaaible Trauma by the Treatment of Enhanced Micro Dosing the Levels of 0.15, Thru 0.33, With a Maintenance Dose of 1 Gram Per Month for Neural Pathway Increase of Non Synthesized Psilocybin, Using the Actual Plant to Regulate the Highjacked Nervous System. - NWTraumatherapies (ClinicalTrials.gov, 2022)

Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications. - Shahar O; Botvinnik A; Esh-Zuntz N; Brownstien M; Wolf R; Lotan A; Wolf G; Lerer B; Lifschytz T. (2022)

Manuel de Yale pour la Thérapie de la Dépression Assistée par la Psilocybine - Guss J; Krause R; Sloshower J. (PsyArXiv, 2022)

Manuel de Yale pour la Thérapie de la Dépression Assistée par la Psilocybine (PsyArXiv, 2022)

Psychedelic compounds directly excite 5-HT2A Layer 5 Pyramidal Neurons in the Prefrontal Cortex through a 5-HT2A Gq -mediated activation mechanism - Schmitz GP; Chiu Y; König GM; Kostenis E; Roth BL; Herman MA. (bioRxiv, 2022)

Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids. - Gotvaldová K; Borovička J; Hájková K; Cihlářová P; Rockefeller A; Kuchař M. (2022)

Body mass index (BMI) does not predict responses to psilocybin. - Spriggs MJ; Giribaldi B; Lyons T; Rosas FE; Kärtner LS; Buchborn T; Douglass HM; Roseman L; Timmermann C; Erritzoe D; Nutt DJ; Carhart-Harris RL. (2022)

A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence - NYU Langone Health (ClinicalTrials.gov, 2022)

Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields. - Strauss D; Ghosh S; Murray Z; Gryzenhout M. (2022)

Psilocin - The "real deal" or an extraction byproduct. - Gutman O; Tenne D; Bretler U. (2022)

5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice - Jefferson SJ; Gregg I; Dibbs M; Liao C; Wu H; Davoudian PA; Sprouse JS; Sherwood AM; Kaye AP; Pittenger C; Kwan AC. (bioRxiv, 2022)

The Missing Piece? A Case for Microglia's Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics. - VanderZwaag J; Halvorson T; Dolhan K; Šimončičová E; Ben-Azu B; Tremblay MÈ. (2022)

Psilocybin reduces symptoms in treatment resistant depression, trial results show. - Iacobucci G. (2022)

Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice. - Glatfelter GC; Pottie E; Partilla JS; Sherwood AM; Kaylo K; Pham DNK; Naeem M; Sammeta VR; DeBoer S; Golen JA; Hulley EB; Stove CP; et al. (2022)

Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial. - O'Donnell KC; Mennenga SE; Owens LT; Podrebarac SK; Baron T; Rotrosen J; Ross S; Forcehimes AA; Bogenschutz MP. (2022)

Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers - Mason N; Szabo A; Kuypers K; Mallaroni P; de la Torre Fornell R; Reckweg J; Tse D; Hutten N; Feilding A; Ramaekers J. (medRxiv, 2022)

Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies. - Calleja-Conde J; Morales-García JA; Echeverry-Alzate V; Bühler KM; Giné E; López-Moreno JA. (2022)

Psilocybin mushrooms for psychological and existential distress: Treatment for a patient with palliative lung cancer. - Patchett-Marble R; O'Sullivan S; Tadwalkar S; Hapke E. (2022)

[Treatment-resistant depression. From classification to new therapies.] - Paganin W; Signorini S; Signorini S; Leccese V; Sciarretta A. (2022)

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. - Goodwin GM; Aaronson ST; Alvarez O; Arden PC; Baker A; Bennett JC; Bird C; Blom RE; Brennan C; Brusch D; Burke L; Campbell-Coker K; et al. (2022)

Psilocybin in Treatment-Resistant Depression. - Madras BK. (2022)

Microdosing with classical psychedelics: Research trajectories and practical considerations. - Wong A; Raz A. (2022)

Five new species of Inosperma from China: Morphological characteristics, phylogenetic analyses, and toxin detection. - Li SN; Xu F; Long P; Liu F; Zhang P; Fan YG; Chen ZH. (2022)

Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes. - Jones GM. (2022)

Serotonergic antidepressant use is associated with weaker psilocybin effects - Gukasyan N; Griffiths RR; Yaden DB; Antoine D; Nayak SM. (PsyArXiv, 2022)

A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression. - Nayak SM; Bari BA; Yaden DB; Spriggs MJ; Rosas FE; Peill JM; Giribaldi B; Erritzoe D; Nutt DJ; Carhart-Harris R. (2022)

Serotonergic antidepressant use is associated with weaker psilocybin effects (PsyArXiv, 2022)

Psilocybin modulation of time-varying functional connectivity is associated with plasma psilocin and subjective effects. - Olsen AS; Lykkebo-Valløe A; Ozenne B; Madsen MK; Stenbæk DS; Armand S; Mørup M; Ganz M; Knudsen GM; Fisher PM. (2022)

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. - Sheppard Pratt Health System (ClinicalTrials.gov, 2022)

Electrical spiking of psilocybin fungi. - Gandia A; Adamatzky A. (2022)

Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial (PsyArXiv, 2022)

Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos? - Dupuis D; Veissière S. (2022)

Are Magic Mushrooms Really Magic?: Psilocybin in the Treatment of Depression. - Balon R. (2022)

Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial). - Jensen ME; Jensen ME; Stenbæk DS; Juul TS; Fisher PM; Ekstrøm CT; Knudsen GM; Fink-Jensen A. (2022)

Mescaline: The forgotten psychedelic. - Vamvakopoulou IA; Narine KAD; Campbell I; Dyck JRB; Nutt DJ. (2022)

An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA) - Beckley Psytech Limited (ClinicalTrials.gov, 2022)

A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy. - Sottile RJ; Vida T. (2022)

Potential Therapeutic Effects of Psilocybin: A Systematic Review. - Goel DB; Zilate S. (2022)

Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies. - Weleff J; Akiki TJ; Barnett BS. (2022)

Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality. - Jones GM; Nock MK. (2022)

Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. - Ko K; Kopra EI; Cleare AJ; Rucker JJ. (2022)

Psilocybin: a revolution in psychedelic medicines in the US? - Silberner J. (2022)

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355 - Ching THW; Kichuk S; DePalmer G; Pittenger C; Kelmendi B. (PsyArXiv, 2022)

Predictors of Psychedelic Experience: A Thematic Analysis. - McCartney AM; McGovern HT; De Foe A. (2022)

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355 (PsyArXiv, 2022)

Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals. - Søndergaard A; Madsen MK; Ozenne B; Armand S; Knudsen GM; Fisher PM; Stenbæk DS. (2022)

Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain's control energy landscape. - Singleton SP; Luppi AI; Carhart-Harris RL; Cruzat J; Roseman L; Nutt DJ; Deco G; Kringelbach ML; Stamatakis EA; Kuceyeski A. (2022)

3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs. - López-Arnau R; Camarasa J; Carbó ML; Nadal-Gratacós N; Puigseslloses P; Espinosa-Velasco M; Urquizu E; Escubedo E; Pubill D. (2022)

A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap. - Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI. (2022)

Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations. - Timmermann C; Watts R; Dupuis D (Transcultural psychiatry, 2022)

If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics. - Dworkin RH; Anderson BT; Andrews N; Edwards RR; Grob CS; Ross S; Satterthwaite TD; Strain EC (The journal of pain, 2022)

Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data. - Barnett BS; Ziegler K; Doblin R; Carlo AD (Journal of psychopharmacology (Oxford, England), 2022)

New investigational agents for the treatment of major depressive disorder. - Pochwat B; Krupa AJ; Siwek M; Szewczyk B (Expert opinion on investigational drugs, 2022)

Prevalence and associations of classic psychedelic-related seizures in a population-based sample. - Simonsson O; Goldberg SB; Chambers R; Osika W; Long DM; Hendricks PS (Drug and alcohol dependence, 2022)

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. - Bogenschutz MP; Ross S; Bhatt S; Baron T; Forcehimes AA; Laska E; Mennenga SE; O'Donnell K; Owens LT; Podrebarac S; Rotrosen J; Tonigan JS; et al. (2022)